Medical & Biotech

‘Pharma bro’ Martin Shkreli launches Substack following prison release

“Pharma bro” Martin Shkreli has launched a newsletter on Substack in the wake of his release from federal prison.The 39-year-old, who was convicted in 2017, was released from a Pennsylvania prison and into a Bureau of Prisons halfway house in New York in May. He launched his free-for-now blog this week and claims it will cover “investing, science and technology.”Shkreli says that he wrote the first post the week before his 18 May release from prison, though it only published on Thursday. In it, he asks if Twitter will end his ban, which has been in place since 2017.The...
Picture for ‘Pharma bro’ Martin Shkreli launches Substack following prison release

Coffee: The Swiss Army Knife of Beverages

The beloved caffeine boost that's become a ritualistic part of nearly everyone's morning actually has some more benefits than a quick energy source. Coffee has a variety of health benefits other than fighting off fatigue, according to, a medical media source that is reviewed and written by medical professionals. Some notable benefits are linked to supporting heart health, lowering the risk of depression, lowering the risk of type 2 diabetes, and even increasing general longevity. These claims are supported by research published by, an academic library supplied by the National Institutes of Health, National Center for Biotechnology Information, and National Library of Medicine. All submissions on the PubMed library are from accredited universities, organizations, and individuals that have undergone a full scientific process and review.
Picture for Coffee: The Swiss Army Knife of Beverages
Seeking Alpha

Revive Therapeutics says FDA agrees to changes to late-stage study for COVID-19 therapy

The U.S. FDA has agreed to new primary efficacy endpoints for Revive Therapeutics' (OTCQB:RVVTF) for bucillamine for mild-to-moderate COVID-19. The agency has accepted the company's Data Access Plan that will allow for the unblinding of the pre-dose selection data. The new efficacy endpoints include the rate of sustained clinical resolution...
Seeking Alpha

EOM Pharmaceuticals files to uplist to Nasdaq

EOM (formerly ImmunoCellular Therapeutics) has two candidates in the clinical stage, EOM613 and EOM147. The former is in phase 2 for cancer cachexia, HIV/AIDS, and rheumatoid arthritis. EOM 147 is in phase 2 for age-related macular degeneration, diabetic retinopathy, and macular edema due to retinal vein occlusion.

Precision, Novartis ink potential $1.4B development deal

DURHAM – Durham-based Precision Biosciences’ genome editing technology has drawn interest – and investment – from another global pharmaceutical giant. This time it’s Novartis. The two companies have announced an exclusive worldwide in vivo gene editing research and development collaboration and license agreement. Precision (Nasdaq:...

Is the Pharmaceutical Industry Ready for Continuous Manufacturing?

Global pharmaceutical manufacturing — valued at more than $405 billion in 2020 — is expected to reach a compound annual growth rate (CAGR) of 11.34% by 2028. With increased consumer awareness and the COVID-19 pandemic spotlighting pharmaceutical drug development, there’s never been a better time to simplify processes, lower production costs and operate on a faster production-to-market schedule.

Biotech Says It Can Program Life To Make New Stuff. Is That True?

Humans love telling things what to do. Anything we can establish, predict, and control — from computers to factories — we can program to get reliable, useful results. Biotechnology has matured to the point where scientists increasingly regard living cells as programmable, but not everyone agrees with using that term. By tinkering with and editing their genes to create all kinds of useful new products, molecules, chemicals and materials at scale, leaders in this field of synthetic biology promise to fundamentally reinvent the way we make things, driven by new and emerging techniques for editing DNA and the seemingly limitless productive potential of biology.

Monkeypox testing expanded to commercial labs

To quickly increase monkeypox testing capacity and access in every community during the ongoing monkeypox outbreak, the Department of Health and Human Services (HHS), through the Centers for Disease Control and Prevention (CDC), began shipping orthopoxvirus tests to five commercial laboratory companies, including the nation’s largest reference laboratories–Aegis Science, Labcorp, Mayo Clinic Laboratories, Quest Diagnostics and Sonic Healthcare.